Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

被引:759
作者
Fonner, Virginia A. [3 ]
Dalglish, Sarah L. [1 ]
Kennedy, Caitlin E. [1 ]
Baggaley, Rachel [2 ]
O'Reilly, Kevin R. [3 ]
Koechlin, Florence M. [2 ]
Rodolph, Michelle [2 ]
Hodges-Mameletzis, Ioannis [2 ]
Grant, Robert M. [2 ,4 ,5 ,6 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[2] WHO, HIV Dept, Geneva, Switzerland
[3] Med Univ South Carolina, Charleston, SC USA
[4] Gladstone Inst, San Francisco, CA USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] San Francisco AIDS Fdn, San Francisco, CA USA
基金
比尔及梅琳达.盖茨基金会;
关键词
HIV; HIV prevention; meta-analysis; preexposure prophylaxis; systematic review; tenofovir; TENOFOVIR DISOPROXIL FUMARATE; SEXUAL RISK BEHAVIOR; BONE-MINERAL DENSITY; DRUG-RESISTANCE; DOUBLE-BLIND; TRANSGENDER WOMEN; ANTIRETROVIRAL PROPHYLAXIS; BANGKOK TENOFOVIR; HETEROSEXUAL MEN; RENAL-FUNCTION;
D O I
10.1097/QAD.0000000000001145
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Preexposure prophylaxis (PrEP) offers a promising new approach to HIV prevention. This systematic review and meta-analysis evaluated the evidence for use of oral PrEP containing tenofovir disoproxil fumarate as an additional HIV prevention strategy in populations at substantial risk for HIV based on HIV acquisition, adverse events, drug resistance, sexual behavior, and reproductive health outcomes. Design: Rigorous systematic review and meta-analysis. Methods: A comprehensive search strategy reviewed three electronic databases and conference abstracts through April 2015. Pooled effect estimates were calculated using random-effects meta-analysis. Results: Eighteen studies were included, comprising data from 39 articles and six conference abstracts. Across populations and PrEP regimens, PrEP significantly reduced the risk of HIV acquisition compared with placebo. Trials with PrEP use more than 70% demonstrated the highest PrEP effectiveness (risk ratio = 0.30, 95% confidence interval: 0.21-0.45, P < 0.001) compared with placebo. Trials with low PrEP use did not show a significantly protective effect. Adverse events were similar between PrEP and placebo groups. More cases of drug-resistant HIV infection were found among PrEP users who initiated PrEP while acutely HIV-infected, but incidence of acquiring drug-resistant HIV during PrEP use was low. Studies consistently found no association between PrEP use and changes in sexual risk behavior. PrEP was not associated with increased pregnancy-related adverse events or hormonal contraception effectiveness. Conclusion: PrEP is protective against HIV infection across populations, presents few significant safety risks, and there is no evidence of behavioral risk compensation. The effective and cost-effective use of PrEP will require development of best practices for fostering uptake and adherence among people at substantial HIV risk. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:1973 / 1983
页数:11
相关论文
共 63 条
[1]   Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial: Concordance With Drug Detection [J].
Amico, K. Rivet ;
Marcus, Julia L. ;
McMahan, Vanessa ;
Liu, Albert ;
Koester, Kimberly A. ;
Goicochea, Pedro ;
Anderson, Peter L. ;
Glidden, David ;
Guanira, Juan ;
Grant, Robert .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 66 (05) :530-537
[2]  
[Anonymous], GUID PREEXP OR PROPH
[3]  
[Anonymous], CONS GUID HIV PREV D
[4]  
[Anonymous], PLOS ONE
[5]  
[Anonymous], ANTIVIR THER
[6]  
[Anonymous], 2015, HPTN 067 ADAPT CAPE
[7]  
[Anonymous], 2014, The Gap Report
[8]  
[Anonymous], VALIDATING MEASURES
[9]  
[Anonymous], PREDICTING EFFECTIVE
[10]  
[Anonymous], 2015, NEAR ELIMINATION HIV